Adimmune Corp

Adimmune Corporation develops, manufactures, and distributes vaccines and other biological products in Taiwan, the United States, China, and internationally. Its products include AdimFlu-S, a quadrivalent influenza vaccine; injectable influenza vaccine suspensions; and a tetanus toxoid alum-precipitated product for preventing tetanus after injury. The company is also developing AdimrSC-2f, a subunit protein-based COVID-19 vaccine, an H5N1 vaccine, and a cell culture-derived Japanese encephalitis vaccine. Formerly Kuo Kwang Serum and Vaccine Manufacture Co., Ltd., it changed its name to Adimmune Corporation in 2001; it was incorporated in 1965 and is headquartered in Taichung, Taiwan.